Table 2.
Guidelines for TKI discontinuation in clinical practice.
| Criteria | FCMLSG [125] | NCCN | ESMO [122] |
|---|---|---|---|
| Age | >18 | >18 | >18 |
| Phase | CP only | CP only | CP only |
| Sokal score | not defined | Not defined | Not a high score |
| BCR–ABL1 transcript | e13a2, e14a2, or e13a2 + e14a2 |
Quantifiable typical transcript | e13a2, e14a2 |
| TKI duration (years) | >5 | >3 | >5 |
| DMR type | MR4.5 | MR4 | MR4.5 |
| DMR duration (years) | >2 | >2 | >2 |
| Re-treatment | Loss of MMR | Loss of MMR or < MR4 | Not defined |
| Prior history | No HSCT, no progression, no resistance, suboptimal response | No prior history of progression or treatment resistance | Optimal response |
Abbreviations: CP = chronic phase, TKI = tyrosine kinase inhibitor, DMR = deep molecular response, MMR = major molecular response, MR = molecular response HSCT = haematopoietic stem cell transplant, FCMLSG= French chronic myeloid leukaemia study group, ESMO = European society for medical oncology, and NCCN = national comprehensive cancer network.